The **first and only** IgG Fc-antibody fragment for the treatment of gMG[1]

Getting your gMG patients started with VYVGART®

VYVGART® (efgartigimod alfa) is indicated for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.[1]

AChR=anti-acetylcholine receptor; Fc=crystallizable fragment; gMG=generalized Myasthenia Gravis; IgG=immunoglobulin G.

VYVGART® dosing information[1]

VYVGART®: ongoing precision treatment

Each vial contains 20 mg/mL of efgartigimod alfa solution.

- The recommended dose of VYVGART® is 10 mg/kg administered as an IV infusion over one hour once weekly for 4 weeks (one treatment cycle).†
- Administer subsequent treatment cycles based on clinical evaluation.

VYVGART® is administered via intravenous infusion.

The MyPATH Patient Support Program will coordinate every aspect of your patient's treatment, from setting up infusions at home or in a clinic to ensuring timely VYVGART® delivery.

An example approach for initiating new patients on VYVGART®

4 weekly infusions (10 mg/kg) for **4** weeks across **3** treatment cycles[1]

CYCLES 1 – 3

4 WEEKS **ON** THERAPY

4 WEEKS **OFF** THERAPY

FOR THE FIRST 3 TREATMENT CYCLES

CYCLES 4+

ADJUST TIME BETWEEN TREATMENT CYCLES BASED ON CLINICAL EVALUATION



Subsequent treatment cycles[1]

- Administer subsequent treatment cycles based on clinical evaluation
- The safety of initiating a subsequent treatment cycle sooner than 4 weeks from the last infusion of the previous treatment cycle has not been established

Tracking gMG symptoms with the MG-ADL

You may find it helpful for your patient to track their gMG symptoms.

Grade	0	1	2	3	Score (0, 1, 2, or 3)
1. Talking	Normal	Intermittent slurring or nasal speech	Constant slurring or nasal, but can be understood	Difficult to understand speech	
2. Chewing	Normal	Fatigue with solid food	Fatigue with soft food	Gastric tube	
3. Swallowing	Normal	Rare episode of choking	Frequent choking necessitating changes in diet	Gastric tube	
4. Breathing	Normal	Shortness of breath with exertion	Shortness of breath at rest	Ventilator dependence	
5. Impairment of ability to brush teeth or comb hair	None	Extra effort, but no rest periods needed	Rest periods needed	Cannot do one of these functions	
6. Impairment of ability to arise from a chair	None	Mild, sometimes uses arms	Moderate, always uses arms	Severe, requires assistance	
7. Double vision	None	Occurs, but not daily	Daily, but not constant	Constant	
8. Eyelid droop	None	Occurs, but not daily	Daily, but not constant	Constant	
				MG-ADL score (items 1-8):	

Patients can use the MG-ADL assessment tool to keep track of their symptoms, with coordination and assistance provided by the MyPATH Patient Support Program.

The MyPATH Patient Support Program can provide updates on changes in your patient's MG-ADL score over time.

What is Minimal Symptom Expression (MSE)?[3]

The term MSE is utilized to describe an MG-ADL score of 0 or 1.

No vaccination is required prior to starting VYVGART®[1]

Physicians should evaluate the need to administer age-appropriate vaccines according to immunization guidelines at least 4 weeks before initiation of VYVGART®.

- For patients that are being treated with VYVGART®, vaccination with live or live attenuated vaccines is not recommended.
- For all other vaccines, vaccination should take place at least 2 weeks after the last infusion of a treatment cycle and 4 weeks before initiating the next cycle.

MG-ADL: © 1997 UT Southwestern Medical Center, Dallas[2]

gMG=generalized Myasthenia Gravis; IgG=immunoglobulin G; MG-ADL=Myasthenia Gravis Activities of Daily Living; MSE=Minimal Symptom Expression.

† In patients weighing 120 kg or more, the recommended dose of VYVGART® is 1200 mg (3 vials) per infusion.

MyPATH

VYVGART® Patient Support Program

Supporting you and your patients with the VYVGART® treatment journey

Enrol your patients in the MyPATH Patient Support Program today!

1-877-697-2840

1-877-697-2844

info@mypathpsp.ca

Monday to Friday, 8 a.m. – 8 p.m. EST
Bilingual services are available.

Please consult the VYVGART® Product Monograph at https://www.argenx.com/product/vyvgart_product_monograph.pdf for more information about contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling argenx Medical Information at 1-800-731-8917.

References: 1. VYVGART® Product Monograph. argenx. September 19th, 2023. **2.** Howard JF, *et al.* 2023. Long-Term Safety, Tolerability, and Efficacy of Efgartigimod (ADAPT+): Interim Results From a Phase 3 Open-Label Extension Study in Participants With Generalized Myasthenia Gravis. *Front Neurol*; 14, 1284444. **3.** Wolfe GI, *et al.* Myasthenia gravis activities of daily living profile. *Neurology.* 1999;52(7):1487-1489. doi: 10.1212/wnl.52.7.1487

argenx MyPATH

MEMBER OF INNOVATIVE MEDICINES CANADA

Pr VYVGART® efgartigimod alfa 400 mg/20 mL